The FDA signaled a structural shift in rare disease drug review with a “Rare Disease Framework Initiative,” aiming to improve consistency and seek external advice rather than rely on a one-size-fits-all approach. The agency plans to review existing policies across the product lifecycle, from preclinical trial engagement through post-marketing requirements. Analysts framed the initiative as an effort to reduce uncertainty for sponsors without broadly “lowering the bar.” With feedback targeted for late October and internal recommendations potentially timed for February, the framework could influence how quickly smaller biotech programs interpret evidence expectations in ultra-rare settings.